Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Ex-Ranbaxy promoters...

    Ex-Ranbaxy promoters to submit asset declarations to Delhi HC in Daiichi Case

    Written by kanchan joshi joshi Published On 2016-12-01T13:34:23+05:30  |  Updated On 1 Dec 2016 1:34 PM IST
    Ex-Ranbaxy promoters to submit asset declarations to Delhi HC in Daiichi Case
    Arguments to be heard in March 2017

    New Delhi: Hearing on the case of enforcement of Singapore arbitration award on Singh brothers on Monday, the High Court has granted three more days to Shivinder Singh and other respondents to declare their assets. This came after Senior advocate Harish Salve, appearing on behalf from Singh Brothers reasoned the delay of submissions to the court as procedural.

    Though the date set for submissions of asset declarations by Singh brothers and other respondents was Monday, but only Malvinder Singh submitted the declarations, while others including Shivinder Singh’s declarations were not submitted, reports
    Business Standard
    .

    Advocate Salve, appearing on the behalf of Ranbaxy assured the court, that the declarations of all the respondents including Singh were ready, but could not be submitted due to procedural issues.

    Concerns were also raised by Salve, on November 4 order of the court against the need for filing of asset declaration by Ranbaxy former owners and other respondents claiming it to be capable of misuse. He added that its could be misused by Daiichi in any inter-party proceedings.

    "The enforcement of the award is in this court. The applicants cannot be allowed to take these declarations to other foreign jurisdictions. It is the foreign court's job to pass similar orders if necessary. I am worried about such carte blanche (complete freedom to act) orders,” Salve added

    Meanwhile, he questioned Daiichi’s veracity to attempt obtain the declarations before continuing with the actual proceedings, added that Singhs are in-charge of several large companies at present, adding that they cannot afford to become defaulters “These declarations have no association with the main matter; let's get on with the real dispute,” he said

    It is decided that the brothers and the other respondents are going to provide the declarations in sealed envelopes.

    Applications in the matter, including the application for modification of the earlier order shall be considered on Feb 1, 2017 and main arguments will be heard from March 27, 2017 onwards.

    There is a running case on Singh brothers in High Court regarding enforcement of Singapore arbitration award of Rs 2562 crores. The former Ranbaxy promoters had objected to the enforcement of Singapore arbitration award in India. In a proceeding on Monday it was said by their supporting lawyer that the enforcement of arbitration award on the two does not have any grounds in India.

    Read Also: Singapore arbitration award of Rs 2,562 crore holds no grounds in India: Ex Ranbaxy Owners
    daiichiformer promotersHarish SalveMalvinder SinghRanbaxyShivinder SinghSingapore arbitration award
    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    kanchan joshi joshi
    kanchan joshi joshi
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok